Earlier this month, Policy Cures released its 2012 G-Finder Survey on Neglected Disease Research and Development. The report discusses current funding and trends from public and private sources for 31 Neglected Tropical Diseases (NTDs), which for this report include HIV/AIDS, tuberculosis and malaria, as well as the seven most common NTDs we focus on at the Global Network.

The report covers total funding for research and development for NTD drugs, vaccines and other tools, as well as basic research and epidemiological studies. Here are a few highlights:

  • In 2011, total reported funding for NTD R&D was just over $3 Billion USD.
  • Overall funding levels changed little from 2010 with repeat funders reducing their investment by only $3.6m (-0.1 percent).
  • Until 2009, global investment in neglected disease R&D had been increasing steadily, but has been in gradual decline thereafter as the impact of the global financial crisis became evident.
  • Both public and philanthropic funding have decreased since the global financial crisis, but industry funding has increased dramatically over the survey period
  • As in previous years, the three ‘top tier’ diseases – HIV/AIDS, malaria and tuberculosis – again received approximately two-thirds of total global neglected disease R&D funding:
    • HIV/AIDS receiving 33.8 percent
    • malaria receiving 18.4 percent
    • TB receiving 17.3 percent
  • The ‘second tier’ diseases – dengue, diarrheal diseases, kinetoplastids, bacterial pneumonia and meningitis, helminth infections and salmonella infections – increased their collective share to almost a quarter of global funding (24.1 percent) in 2011, demonstrating a shift from the top tier diseases.
  • The ‘third tier’ diseases – trachoma, leprosy, Buruli ulcer and rheumatic fever – collectively receiving less than one percent of global R&D funding.
  • The public sector continued to play a key role in neglected disease R&D, providing almost two-thirds of global funding. The U.S. maintained its position as the pre-eminent funder of NTD R&D, accounting for slightly less than 70 percent of all public funding. Several public funders increased funding in 2011:
    • The European Commission (up $12.7m)
    • Australia (up $6.7m)
    • The Netherlands (up $6.1m)
  • As in 2010, the philanthropic sector contributions ($570.6m, 18.7%) were closely matched by investments from industry ($525.1m, 17.2%).


Despite initial fears, the global financial crisis has not had a dramatic impact on overall NTD R&D funding, with public funding essentially stable and decreases from the philanthropic sector largely offset by increased industry funding. See the full report here.